Form 4 for CVS CVS Health
Accepted 2024-04-03 00:00:00 ET · period of report 2024-04-01 · accession 0001127602-24-012257 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-04-03 | 2024-04-01 | CVS | Mandadi Tilak | EVP, CTO | A - Grant | $0.00 | +16.3K | 82.9K | +25% | $0 |
| D | 2024-04-03 | 2024-04-01 | CVS | Mandadi Tilak | EVP, CTO | A - Grant | $79.56 | +67.9K | 67.9K | New | +$5.40M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock (RSU) | 2024-04-01 | A | A | 16,339 | $0.00 | 82,904 | D | — | — | |
| 2 | Derivative | Stock Option | 2024-04-01 | A | A | 67,920 | $79.56 | 67,920 | D | $79.56 · 2025-04-01 to 2034-04-01 | 67,920 Common Stock | (F2) Option becomes exercisable in four equal annual installments, commencing 4/1/2025. |